Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this early in its development. Over the past year, Erasca has returned about 13.8x, which puts a lot of expectation into the current share price. Encouraging early data for ERAS-0015 and new collaborations can support high growth expectations, while heavy funding needs for ongoing trials and future...

Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a sharp move in the stock. See our latest analysis for Erasca. The latest ERAS-0015 update and follow-on offering sit against a powerful run in Erasca’s stock, with a 1-day share price return of 8.94%, a 30-day share price return of 38.79%, and a year-to-date share price return of 443.18%. The...

Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid tumors, including KRAS G12X pancreatic cancer. An interesting angle for investors is that ERAS-0015 is being advanced toward multiple potentially registration-enabling trials across both pancreatic and lung cancer, signaling an ambition to build a broader RAS-focused franchise. We’ll now...

Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, strengthening investor confidence that the drug could become a potential treatment option for difficult-to-treat RAS-mutant cancers. Based on data from the phase 1 clinical […]